Biologic Manufacturers Should Expect Antitrust Scrutiny

Law360 (April 17, 2019, 4:16 PM EDT) -- Democrats and Republicans agree on few issues, but one of them is that something must be done about the high cost of medical drugs in the United States. While government antitrust enforcers have paid much attention over the last two decades to competition from generic pharmaceuticals, there has recently been antitrust scrutiny by private plaintiffs on competition among biologics and their interchangeable biosimilars.

In particular, various plaintiffs have recently filed antitrust class actions in the Northern District of Illinois against AbbVie Inc., the manufacturer of the biologic Humira, and numerous biosimilar manufacturers.

The complaints’ allegations track the antitrust principles of “reverse...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!